Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43871   clinical trials with a EudraCT protocol, of which   7290   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2013-001506-29
    Sponsor's Protocol Code Number:P11-06/BF2.649
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:
    Date on which this record was first entered in the EudraCT database:2021-06-17
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2013-001506-29
    A.3Full title of the trial
    Double blind, multicentre, randomized, placebo-controlled trial to evaluate safety and efficacy of pitolisant in children from 6 to less than 18 years with narcolepsy with/without cataplexy, followed by a prolonged open-label period.
    Trial placebo-controllato, randomizzato, multicentrico e in doppio cieco condotto per valutare la sicurezza e l'efficacia del pitolisant nei bambini di et¿ compresa tra i 6 e meno di 18 anni affetti da narcolessia con/senza cataplessia, seguito da un periodo open-label prolungato.
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Clinical study to evaluate eficacy of Pitolisant for children from 6 to 18 years with narcolepsy with/without cataplexy
    Studio di ricerca per valutare l'effetto di Pitolisant per il trattamento di bambini e adolescenti di et¿ tra i 6 e i 18 anni con narcolessia con o senza cataplessia
    A.3.2Name or abbreviated title of the trial where available
    P11-06
    P11-06
    A.4.1Sponsor's protocol code numberP11-06/BF2.649
    A.7Trial is part of a Paediatric Investigation Plan Yes
    A.8EMA Decision number of Paediatric Investigation PlanP/200/2013
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorBIOPROJET PHARMA
    B.1.3.4CountryFrance
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportBIOPROJET
    B.4.2CountryFrance
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationBIOPROJET
    B.5.2Functional name of contact pointPatricia Rodriguez
    B.5.3 Address:
    B.5.3.1Street AddressRue Rameau 9
    B.5.3.2Town/ cityParigi
    B.5.3.3Post code75002
    B.5.3.4CountryFrance
    B.5.4Telephone number00330147036631
    B.5.5Fax number00330147036630
    B.5.6E-mailp.rodriguez@bioprojet.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community Yes
    D.2.5.1Orphan drug designation numberEU/3/07/459
    D.3 Description of the IMP
    D.3.1Product namePitolisant
    D.3.2Product code BF2.649
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNPitolisant
    D.3.9.1CAS number 903576-44-3
    D.3.9.2Current sponsor codeBF2.649
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number5
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community Yes
    D.2.5.1Orphan drug designation numberEU/3/07/459
    D.3 Description of the IMP
    D.3.1Product namePitolisant
    D.3.2Product code Bf2.649
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNPitolisant
    D.3.9.1CAS number 903576-44-3
    D.3.9.2Current sponsor codeBF2.649
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number20
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboTablet
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Narcolepsy
    Narcolessia
    E.1.1.1Medical condition in easily understood language
    neurological disorder that affects the control of sleep and wakefulness
    eccessiva sonnolenza diurna
    E.1.1.2Therapeutic area Diseases [C] - Nervous System Diseases [C10]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level LLT
    E.1.2Classification code 10028715
    E.1.2Term Narcolepsy with cataplexy
    E.1.2System Organ Class 10029205 - Nervous system disorders
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 22.1
    E.1.2Level LLT
    E.1.2Classification code 10048322
    E.1.2Term Narcolepsy aggravated
    E.1.2System Organ Class 10029205 - Nervous system disorders
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level PT
    E.1.2Classification code 10028713
    E.1.2Term Narcolepsy
    E.1.2System Organ Class 10029205 - Nervous system disorders
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 21.1
    E.1.2Level LLT
    E.1.2Classification code 10048323
    E.1.2Term Cataplexy aggravated
    E.1.2System Organ Class 10029205 - Nervous system disorders
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level PT
    E.1.2Classification code 10007737
    E.1.2Term Cataplexy
    E.1.2System Organ Class 10029205 - Nervous system disorders
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level PT
    E.1.2Classification code 10007737
    E.1.2Term Cataplexy
    E.1.2System Organ Class 10029205 - Nervous system disorders
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level PT
    E.1.2Classification code 10028713
    E.1.2Term Narcolepsy
    E.1.2System Organ Class 10029205 - Nervous system disorders
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To evaluate the efficacy of pitolisant in reducing residual Excessive Daytime Sleepiness (EDS) and the number of cataplectic episodes (for patients with cataplexy)
    Valutare l'efficacia del pitolisant nella riduzione dell'eccessiva sonnolenza diurna (ESD) e del numero di episodi cataplettici (nei pazienti con cataplessia)
    E.2.2Secondary objectives of the trial
    To determine safety in children and adolescents;
    To assess the long-term safety of BF2.649 in the treatment of EDS in narcoleptic patients with or without cataplexy;
    To assess the drug-drug interactions with possible concomitant therapies.
    To assess the efficacy of long-term therapy with BF2.649 on EDS after a prolonged treatment period.
    Definirne la sicurezza in bambini e adolescenti.
    Valutare la sicurezza a lungo termine del BF2.649 nel trattamento dell'ESD in pazienti narcolettici con o senza cataplessia.
    Valutare le interazioni farmaco-farmaco con possibili terapie concomitanti.
    Valutare l'efficacia della terapia a lungo termine con BF2.649 contro l'ESD dopo un periodo di trattamento prolungato.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1) Male and female children from 6 to less than 18 years of age (until V8) suffering from narcolepsy with or without cataplexy - meeting the International Classification of Sleep Disorders (ICSD-3) criteria (narcolepsy type 1 and 2). Diagnosis confirmed with polysomnography and Multiple Sleep Latency Test for patients without cataplexy (if these examinations were not performed within the last 12 months)
    2) PDSS score = 15 during baseline period (V1+V2) / 2.
    3) Patients should be free of non-authorized medication, in particular psychostimulant treatments as from the screening visit (V0) onwards.
    4) Parents – and patients old enough to understand who have expressed a willingness to participate in the study, who have signed and dated the informed consent form prior to beginning protocol required procedures.
    5) In the opinion of the investigator, the patient must have adequate support to comply with the entire study requirements as described in the protocol (e.g., transportation to and from trial site, self rating scales and diaries completion, drug compliance, scheduled visits, tests).
    6) Female pubescent patients shall use a birth control method, judged efficient by the investigator, throughout the study and during the month following treatment discontinuation.
    7) Patients should benefit from appropriate healthy insurance system (only applicable where mandatory e.g. in France).
    1) Bambini e bambine di età compresa tra i 6 e meno di 18 anni (fino a V8) affetti da narcolessia con o senza cataplessia che soddisfano i criteri previsti dalla Classificazione internazionale dei disturbi del sonno (ICSD-3) (narcolessia di tipo 1 e 2). Diagnosi confermata tramite polisonnografia e test di latenza multipla del sonno in caso di pazienti senza cataplessia (se questi esami non sono già stati effettuati negli ultimi 12 mesi)
    2) Punteggio PDSS = 15 durante il periodo di baseline (V1 + V2) / 2.
    3) A partire dalla visita di screening (V0) in avanti ai pazienti non è consentito assumere farmaci non autorizzati, in particolare farmaci psicostimolanti.
    4) Genitori – e pazienti abbastanza grandi per capire che hanno espresso la propria volontà di partecipare allo studio, che hanno firmato e datato il modulo di consenso informato prima dell'inizio delle procedure previste dal protocollo.
    5) A giudizio del ricercatore è necessario che il paziente possa contare su un supporto adeguato che gli permetta di soddisfare tutti i requisiti previsti dallo studio come descritto nel protocollo (ad es., spostamento da e verso la sede del trial, compilazione delle scale di autovalutazione e dei diari, assunzione dei farmaci, visite programmate, test).
    6) Le pazienti femmine in età puberale dovranno adottare un metodo contraccettivo, giudicato efficiente dal ricercatore, per tutta la durata dello studio e per il mese successivo alla conclusione del trattamento.
    7) I pazienti dovranno disporre di un appropriato sistema di assicurazione sanitaria (applicabile solo dove obbligatorio come ad es. in Francia).
    E.4Principal exclusion criteria
    1) Any other conditions that can be considered the primary causes of EDS: such as sleep related breathing disorders as defined by a sleep Apnea Index = 5 per hour or/and an Apnea/Hypopnea Index = 10 per hour, chronic sleep deprivation, circadian sleep wake rhythm disorder or any other medical or neurological causes that could account for narcolepsy symptoms associated with EDS.
    2) Cataplectic patients treated by anticataplectics (SNRI, SSRI, sodium oxybate) which are not under a stable treatment since at least 4 weeks at the time of inclusion (V2).
    3) Patients treated for cataplexy or any other pathology, by tricyclic antidepressants (clomipramine, imipramine, mirtazapine, desmethylimipramine and protriptyline) are not authorized because they display histamine H1 receptor antagonist activity.
    4) The use of pitolisant within a 30-day period prior to initial screening visit (V0) for this trial.
    5) Current or recent (within one year) history of a substance abuse or dependence disorder including alcohol abuse as defined in Diagnostic and Statistical Manual of Mental Disorders (DSM-IV).
    6) Any significant abnormality of the electrocardiogram and particularly Fridericia’s QTc interval (QTcF = QT/3¿ 60/HR) higher than 450ms.
    7) Patients with severe depression (CDI = 16)
    8) Patient with suicidal risk (C-SSRS)
    9) Positive urinary drug testing (test applicable to patients from 12 years)
    10) Pregnancy (defined as positive ß-HCG blood test), breast-feeding, or patients and unable to use an efficient method of birth control shall not be included in the study (for pubescent female only).
    11) Patients with severe hepatic Impairment (Child Pugh C) or with any other significant abnormality in the physical examination or clinical laboratory results.
    12) Psychiatric and neurological disorders, such as moderate or severe psychosis or dementia, depression, history of seizure disorder or other problem that, in the investigator’s opinion, would preclude the patient’s participation and completion of this trial or comprise reliable representation of subjective symptoms.
    13) Active clinically significant illness, including unstable cardiovascular, endocrine, neoplastic, gastrointestinal, haematological, hepatic, immunologic, metabolic, neurological (other than narcolepsy/cataplexy), pulmonary, and/or renal disease which could interfere with the study conduct or counter-indicate the study treatments or place the patient at risk during the trial or compromise the study objectives.
    14) Prior severe adverse reactions to CNS stimulants.
    15) Known hypersensitivity to the tested treatment including active substance and excipients.
    16) The inability to continue daily activities safely, without the use of treatment against EDS.
    17) Any patient presenting congenital galactosemia, glucose-galactose malabsorption or lactase deficiency due to the presence of lactose in investigational treatments.
    18) Patients participating in another study or being in a follow–up period for another study.
    19) Cannot be contacted in case of emergency.
    1) Qualsiasi altra condizione che possa essere considerata una delle cause principale di ESD: ad esempio disturbi respiratori nel sonno secondo la definizione data dall'Indice di apnee nel sonno =5 all'ora o/e dall'Indice di apnea/ipopnea =10 all'ora, deprivazione cronica di sonno, disturbi del ritmo circadiano sonno-veglia oppure qualsiasi altra causa medica o neurologica che possa spiegare i sintomi della narcolessia associata a ESD.
    2) Pazienti cataplettici sottoposti a trattamento con anticataplettici (SNRI, SSRI, sodio oxibato) che al momento dell'inclusione (V2) non seguono un trattamento stabile da almeno 4 settimane.
    3) Pazienti sottoposti a trattamento per la cataplessia o per qualsiasi altra patologia mediante somministrazione di antidepressivi triciclici (clomipramina, imipramina, mirtazapina, desmetilimipramina e protriptilina) non autorizzati in quanto mostrano un'attività antagonista dei recettori H1 dell'istamina.
    4) L'uso di pitolisant entro un periodo di 30 giorni precedente alla visita di screening iniziale (V0) di questo trial.
    5) Anamnesi corrente o recente (entro un anno) di abuso di sostanze o disturbo da dipendenza, compreso l'abuso di alcol, come da definizione del Manuale diagnostico e statistico dei disturbi mentali (DSM-IV).
    6) Qualsiasi anomalia significativa nell'elettrocardiogramma, in particolare se l'intervallo QTc di Fridericia (QTcF = QT/3¿ 60/HR) risulta superiore a 450 ms.
    7) Pazienti con grave depressione (CDI = 16)
    8) Pazienti con tendenze suicide (C-SSRS)
    9) Narcotest urinario positivo (test applicabile ai pazienti con più di 12 anni)
    10) Le pazienti in gravidanza (confermata dalla positività del test ematico ß-HCG), in allattamento o non in grado di adottare un metodo contraccettivo efficace non verranno incluse nello studio (solo per pazienti femmine in età puberale).
    11) Pazienti con grave insufficienza epatica (classificazione di Child Pugh C) oppure con qualsiasi altra significativa anomalia emersa dall'esame fisico o dai risultati clinici di laboratorio.
    12) Disturbi psichiatrici e neurologici quali ad es. grave o moderata psicosi o demenza, depressione, storia di disturbi convulsivi o altro problema che, a giudizio del ricercatore, possa precludere la partecipazione del paziente e il completamento di questo trial o compromettere l'affidabile interpretazione di sintomi soggettivi.
    13) Malattia attiva clinicamente significativa tra cui malattie instabili di tipo cardiovascolare, endocrina, neoplastica, gastrointestinale, ematologica, epatica, immunologica, metabolica, neurologica (diversa dalla narcolessia/cataplessia), polmonare e/o renale che possa interferire con la condotta dello studio, rivelarsi controindicata per i trattamenti previsti dallo studio, rappresentare un rischio per il paziente oppure compromettere gli obiettivi dello studio.
    14) Gravi reazioni avverse pregresse a stimolanti del SNC.
    15) Nota ipersensibilità al trattamento testato compresi il principio attivo e gli eccipienti.
    16) Incapacità di svolgere le attività quotidiane in sicurezza senza l'uso del trattamento contro l'ESD.
    17) Qualsiasi paziente affetto da galattosemia congenita, malassorbimento di glucosio - galattosio o deficit di lattasi per la presenza di lattosio nei trattamenti sperimentali.
    18) Pazienti che partecipano ad un altro studio o che si trovano nella fase di follow–up di un altro studio.
    19) Impossibilità di essere contattati in caso di emergenza.
    E.5 End points
    E.5.1Primary end point(s)
    Change in the intensity and frequency of symptoms of narcolepsy (EDS and cataplexy) as measured by the Ullanlinna Narcolepsy Scale (UNS) between baseline: [V1 score (D-14) + V2 score (D0)]/2 and the end of treatment: [V6 score (D49) + V7 score (D56)]/2. We will compare the results between pitolisant and placebo groups.
    Variazione nell’intensità e frequenza dei sintomi della narcolessia (ESD e cataplessia) misurata dalla Scala di Narcolessia Ullanlinna (UNS) tra il baseline: [Punteggio V1 (D-14) + punteggio V2 (D0)]/2 e la fine del trattamento: [Punteggio V6 (D49) + punteggio V7 (D56)]/2. Metteremo a confronto i risultati tra i gruppi trattati con il pitolisant e con il placebo.
    E.5.1.1Timepoint(s) of evaluation of this end point
    between baseline: [V1 score (D-14) + V2 score (D0)]/2 and the end of treatment: [V6 score (D49) + V7 score (D56)]/2.
    tra la baseline: [Punteggio V1 (D-14) + punteggio V2 (D0)]/2 e la fine del trattamento: [Punteggio V6 (D49) + punteggio V7 (D56)]/2
    E.5.2Secondary end point(s)
    - Changes in EDS as measured by the maintenance of wakefulness test (MWT) between baseline and V7, in pitolisant and placebo groups.
    - Change in EDS measured by the Paediatric Daytime Sleepiness Scale (PDSS) between baseline: [V1 score (D-14) + V2 score (D0)]/2 and the end of treatment: [V6 score (D49) + V7 score (D56)]/2. We will compare the results between pitolisant and placebo groups.
    - Changes in EDS as measured by the Child and Adolescent Sleepiness Scale (CASS) between baseline and the end of treatment, in pitolisant and placebo groups.
    - Changes in the average number of cataplexy episodes per weeks (recorded in sleep diary by patient and/or parent/teacher) between the 2 weeks of baseline and the 2 weeks of end study treatment period (V6, V7), in pitolisant and placebo groups.
    - Differences in weekly frequency of cataplexy episodes (recorded in sleep diary by patient and/or parent/teacher) between baseline and the 4 weeks of stable treatment period (V4 to V7), in pitolisant and placebo groups.
    - Severity of EDS measured by the Clinical Global Impression of severity and change. Changes between baseline and V6, V7, in pitolisant and placebo groups.
    - Severity of cataplexy measured by the Clinical Global Impression of severity and change. Changes between baseline and V6, V7, in pitolisant and placebo groups.
    - Changes between baseline and V6 will be compared for the TEA-Ch test, in pitolisant and placebo groups.
    - Comparison between placebo and pitolisant groups on:
    - Withdrawal symptoms questionnaire (DSM IV)
    - Patients' Global Opinion on treatment effect at the end of treatment if able to express himself. If not will be reported either by parents or teachers.
    - Changes between baseline and at each visit of the open-label period in EDS.
    - Safety assessment will be done on monitoring of adverse events, physical examination, vital signs, ECG and Blood Laboratory tests modifications and the mood appraisal throughout the study.
    - Variazioni nell'ESD in base ai valori misurati dall'MWT (Maintenance of wakefulness test - Test di mantenimento della veglia) tra la baseline e la V7 nei gruppi trattati con il pitolisant e con il placebo.
    -Variazioni nell’ESD in base ai valori misurati dalla Scala di sonnolenza diurna pediatrica (PDSS) tra il baseline: [Punteggio V1 (D-14) + punteggio V2 (D0)]/2 e la fine del trattamento: [Punteggio V6 (D49) + punteggio V7 (D56)]/2. Verranno messi a confronto i risultati tra i gruppi trattati con il pitolisant e con il placebo.
    - Variazioni nell'ESD in base ai valori misurati dalla Scala di sonnolenza per bambini e adolescenti (CASS) tra la baseline e la fine del trattamento nei gruppi trattati con il pitolisant e con il placebo.
    - Variazione nel numero medio di episodi cataplettici per settimane (registrati nel diario del sonno dal paziente e/o dal genitore/insegnante) tra le 2 settimane di baseline e le 2 settimane finali del periodo di trattamento previsto dallo studio (V6, V7) nei gruppi trattati con il pitolisant e con il placebo.
    - Differenze nella frequenza settimanale di episodi cataplettici (registrati nel diario del sonno dal paziente e/o dal genitore/insegnante) tra la baseline e le 4 settimane del periodo di trattamento stabile (da V4 a V7) nei gruppi trattati con il pitolisant e con il placebo.
    - Gravita' dell'ESD misurata dall'Impressione clinica globale della gravit¿ e del cambiamento. Variazioni tra la baseline e V6, V7 nei gruppi trattati con il pitolisant e con il placebo.
    - Gravita' della cataplessia misurata dall'Impressione clinica globale della gravit¿ e del cambiamento. Variazioni tra la baseline e V6, V7 nei gruppi trattati con il pitolisant e con il placebo.
    - Le variazioni tra la baseline e V6 verranno confrontate utilizzando il test TEA-Ch nei gruppi trattati con il pitolisant e con il placebo.
    - Confronto tra i gruppi trattati con il pitolisant e con il placebo su:
    - Questionario sui sintomi da astinenza (DSM IV)
    - Opinione generale dei pazienti, se in grado di esprimersi autonomamente, sull'effetto del farmaco al termine del trattamento. In caso contrario verr¿ comunicata dai genitori o dagli insegnanti.
    - Variazioni in termini di ESD tra la baseline e in occasione di ciascuna visita del periodo open-label.
    - La valutazione della sicurezza comprender¿ il monitoraggio degli eventi indesiderati, un esame fisico, una valutazione dei segni vitali, un ECG, analisi del sangue di laboratorio e una valutazione dell'umore nel corso dell'intero studio.
    E.5.2.1Timepoint(s) of evaluation of this end point
    Throughtout the study
    durante lo studio
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response Yes
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other Yes
    E.8.1.7.1Other trial design description
    Seguito da 1 settimana di placebo in singolo cieco. Seguito dal periodo prolungato in aperto
    Followed by 1 week of placebo single blind. Then followed by a prolonged open-label period
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned2
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA4
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Russian Federation
    Italy
    Netherlands
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    LVLS
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years2
    E.8.9.1In the Member State concerned months24
    E.8.9.1In the Member State concerned days73
    E.8.9.2In all countries concerned by the trial years2
    E.8.9.2In all countries concerned by the trial months24
    E.8.9.2In all countries concerned by the trial days73
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 Yes
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) Yes
    F.1.1.5.1Number of subjects for this age range: 48
    F.1.1.6Adolescents (12-17 years) Yes
    F.1.1.6.1Number of subjects for this age range: 48
    F.1.2Adults (18-64 years) No
    F.1.3Elderly (>=65 years) No
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally Yes
    F.3.3.6.1Details of subjects incapable of giving consent
    Patient under age incapatible of giving consent personally.Informed Consent form will be signed by each patient (if old enough to understand) and both parents (or their legal representative) before the enrolment in the study
    Paziente minorenne incapace di dare il consenso personale. Consenso informato sar¿ firmato da ciascun paziente (se abbastanza adulto per capire) ed entrambi i genitori (o il loro rappresentante legale) prima l'iscrizione nello studio
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state37
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 71
    F.4.2.2In the whole clinical trial 108
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    The double blind phase will be followed by an open label period if patients wish to participate to have treatment access. Neither specific treatment or care after the patient participation in the trial are anticipated. It is assumed that the subject will be treated according to the usual physician clinical practice.
    La fase in doppio cieco sara' seguito da un periodo in aperto se i pazienti desiderano partecipare per avere accesso al trattamento. N¿ trattamento o cura specifica dopo la partecipazione del paziente alla sperimentazione sono previsti. Si presume che il paziente sar¿ trattato secondo la normale pratica clinica medico.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2016-04-29
    N.Ethics Committee Opinion of the trial application
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion
    P. End of Trial
    P.End of Trial Status
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 03 11:54:35 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA